BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 11342454)

  • 1. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.
    Gianni' M; Kalaç Y; Ponzanelli I; Rambaldi A; Terao M; Garattini E
    Blood; 2001 May; 97(10):3234-43. PubMed ID: 11342454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells.
    Duprez E; Lillehaug JR; Gaub MP; Lanotte M
    Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
    Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
    Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
    Wu D; Shao K; Zhou Q; Sun J; Wang Z; Yan F; Liu T; Wu X; Ye B; Huang H; Zhou Y
    Cell Physiol Biochem; 2018; 48(6):2286-2301. PubMed ID: 30114705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential gene expression in retinoic acid-induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells.
    Lee KH; Chang MY; Ahn JI; Yu DH; Jung SS; Choi JH; Noh YH; Lee YS; Ahn MJ
    Biochem Biophys Res Commun; 2002 Sep; 296(5):1125-33. PubMed ID: 12207890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
    Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
    Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant AF-2 domain of PML-RARalpha in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARalpha and its down-regulation in acute promyelocytic leukemia.
    Kitamura K; Kiyoi H; Yoshida H; Saito H; Ohno R; Naoe T
    Leukemia; 1997 Nov; 11(11):1950-6. PubMed ID: 9369431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells.
    Jing Y; Xia L; Lu M; Waxman S
    Oncogene; 2003 Jun; 22(26):4083-91. PubMed ID: 12821942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
    Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
    Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the peptidyl-prolyl-isomerase Pin1 enhances the responses of acute myeloid leukemia cells to retinoic acid via stabilization of RARalpha and PML-RARalpha.
    Gianni' M; Boldetti A; Guarnaccia V; Rambaldi A; Parrella E; Raska I; Rochette-Egly C; Del Sal G; Rustighi A; Terao M; Garattini E
    Cancer Res; 2009 Feb; 69(3):1016-26. PubMed ID: 19155306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.
    Benedetti L; Grignani F; Scicchitano BM; Jetten AM; Diverio D; Lo Coco F; Avvisati G; Gambacorti-Passerini C; Adamo S; Levin AA; Pelicci PG; Nervi C
    Blood; 1996 Mar; 87(5):1939-50. PubMed ID: 8634442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
    Duprez E; Lillehaug JR; Naoe T; Lanotte M
    Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia.
    Niitsu N; Higashihara M; Honma Y
    Exp Hematol; 2002 Nov; 30(11):1273-82. PubMed ID: 12423680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating effects on acute promyelocytic leukemia cells.
    Gianní M; Li Calzi M; Terao M; Guiso G; Caccia S; Barbui T; Rambaldi A; Garattini E
    Blood; 1996 Feb; 87(4):1520-31. PubMed ID: 8608243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
    Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways.
    Parrella E; Gianni' M; Cecconi V; Nigro E; Barzago MM; Rambaldi A; Rochette-Egly C; Terao M; Garattini E
    J Biol Chem; 2004 Oct; 279(40):42026-40. PubMed ID: 15292163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
    Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
    J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ; Chen LJ; Zhou GB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
    Giannì M; de Thé H
    Leukemia; 1999 May; 13(5):739-49. PubMed ID: 10374879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
    Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
    Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.